ABIOGEN AND ORYX SIGN LICENSE AGREEMENT

The license agreement grants Oryx the exclusive license to market the speciality Clasteon (the bisphosphonate Disodium Clodronate) in Canada. Oryx Pharmaceutical launched Clasteon (R) 400 mg capsules in May 2004 and currently purchases the finished product from Abiogen which manufactures it at its new facility located in the industrial area of Pisa. Abiogen Pharma, born in 1997, is a fully integrated private Italian Pharmaceutical Company involved in R&D, Production and Marketing. Abiogen owns a prestigious R&D Pipeline and showed along the years significant skills in innovative compound development, also broadening out to the biotechnological field.

Genetic Engineering News (http://www.genengnews.com/news/bnitem.aspx?name=554113XSL_NEWSML_TO_NEWSML_WEB.xml)